2814: Indication for CIBMTR Data Reporting

The Indication for CIBMTR Data Reporting (2814) Form collects information to initiate CIBMTR reporting on the appropriate research or data collection forms. This form must be completed for the first indication requiring the individual to register for a CIBMTR Research ID (CRID) and any subsequent infusions the recipient received.

Links to Sections of Form:
Reporting process
Q1 – 2: Indication
Q3 – 12: Infusion
Q13 – 15: Non-Cellular Therapy

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to reference the historical Manual Change History for this form, please reference the retired manual section on the Retired Forms Manuals webpage.

Date	Manual Section	Add/Remove/Modify	Description
10/24/2025	2814: Indication for CIBMTR Data Reporting	Add	MIBG blue box added above Q4: Infusion for Low Blood Counts Following MIBG Therapy: An infusion given as a ‘rescue’ for low blood counts following MIBG therapy is not reported as a HCT. Refer to the 2026: Neuroblastoma Pre-Infusion Manual for more information.
10/24/2025	2814: Indication for CIBMTR Data Reporting	Modify	Instructions updated when an allogeneic infusion is considered a new transplant or an allogeneic boost, dependent upon the indication: Graft failure: Additional stem cells are required because the ANC did not recover following HCT (primary graft failure), or hematopoietic recovery indefinitely declined after the initial hematopoietic recovery or hematopoietic recovery (secondary graft failure) Autologous infusion: If autologous cells are infused for this reason, this is considered an autologous rescue; in this case, reporting will continue under the prior HCT date, and a new Pre-TED form is not required. Allogeneic infusion: If allogeneic cells are infused, regardless of whether a new allogeneic donor or a prior allogeneic donor is used, this is considered a subsequent HCT. A new Pre-TED is required, and a new set of follow-up forms will come due, as applicable. Poor graft function / insufficient donor chimerism: Additional stem cells are required because hematopoietic recovery was deemed insufficient or too slow for survival following previous high-dose therapy and HCT. Autologous infusion: If autologous cells are infused for this reason, this is considered an autologous rescue. Reporting will continue under the prior HCT date, and a new Pre-TED form is not required. If allogeneic cells are infused, this would be considered a subsequent HCT, and a new Pre-TED is required, and a new set of follow up forms will come due, as applicable. Allogeneic infusion using a prior allogeneic donor: If allogeneic cells from a prior donor are infused, this is considered an allogeneic boost. Reporting will continue under the prior HCT date, and the Donor Cellular Infusion (2199) Form is required. Allogeneic infusion using a new allogeneic donor: If allogeneic cells are infused using a new allogeneic donor, this is considered a subsequent HCT. A new Pre-TED is required, and a new set of follow-up forms will come due, as applicable. In the case of a stable, mixed donor chimerism, the infusion of additional cells (usually lymphocytes and not mobilized stem cells) is typically classified as a DCI. Verify with the transplant physician that the cells given should be reported as a subsequent transplant and that stable, mixed chimerism is the reason for the transplant. However, in the case of declining chimerism – when the percentage of donor cells is sequentially decreasing on several studies, indicating possible impending graft failure – additional stem cells are required. Usually, the donor chimerism has fallen below 30-50%.
1/28/2025	2814: Indication for CIBMTR Data Reporting	Modify	Added new floating text to the non-cellular therapy option: Indicate whether the individual will be receiving an Infusion (e.g., hematopoietic cellular transplant (HCT), gene therapy, cellular therapy), Marrow toxic injury, or Non-cellular therapy (e.g., study enrollment, chemotherapy, immunotherapy, etc.).
1/28/2025	2814: Indication for CIBMTR Data Reporting	Remove	Removed the red warning box: Non-cellular Therapy: There are currently no active studies for this option. If this seems to be incorrect, submit a CIBMTR Center Support ticket
1/28/2025	2814: Indication for CIBMTR Data Reporting	Add	New blue note box added: CMS Innovation Center’s Cell and Gene Therapy (CGT) Access Model for Sickle Cell Disease (SCD) Select “non-cellular therapy” when completing this form for the first time for a CRID to be enrolled in the CMS Innovation Center’s Cell and Gene Therapy (CGT) Access Model for Sickle Cell Disease (SCD). Contact CIBMTR Center Support with any questions.
7/26/2024	2814: Indication for CIBMTR data reporting	Add	Version 5 of the Indication for CIBMTR Data Reporting section of the Forms Instructions Manual released. Version 5 corresponds to revision 5 of the Form 2814.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.